VolitionRX Ltd (NASDAQ:VNRX) CFO David Matthew Kratochvil acquired 10,000 shares of the stock in a transaction dated Wednesday, October 5th. The shares were acquired at an average cost of $5.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at approximately $50,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of VolitionRX Ltd (NASDAQ:VNRX) traded up 4.93% during mid-day trading on Thursday, hitting $5.11. The stock had a trading volume of 79,638 shares. The stock has a 50 day moving average price of $4.50 and a 200-day moving average price of $3.70. VolitionRX Ltd has a 52-week low of $3.05 and a 52-week high of $5.86. The company’s market cap is $120.19 million.

VolitionRX (NASDAQ:VNRX) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.01. On average, equities analysts expect that VolitionRX Ltd will post ($0.56) earnings per share for the current fiscal year.

Several analysts have commented on VNRX shares. HC Wainwright set a $10.00 price objective on VolitionRX and gave the company a “buy” rating in a report on Thursday, September 8th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $10.00 price target (down from $12.00) on shares of VolitionRX in a research note on Wednesday, September 7th.

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

5 Day Chart for NASDAQ:VNRX

Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.